investor login

contact

team

dedicated funds

news

 portfolio

CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. The Barostim neo™ uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. The Barostim neo can be adjusted to meet each patient’s individual therapy needs.

IPO in June 2021 (NASDAQ: CVRX).

 

VISIT WEBSITE

HVP VI, Med Tech, Public

back to portfolio

contact

© hatteras venture partners | all rights reserved | terms + privacy | site credit

 team

 portfolio

news

home

Hatteras Venture Partners is a venture capital firm that builds transformational companies in areas of health innovation.

dedicated funds

contact

 team

dedicated funds

news

home

 portfolio